Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Multiple Myeloma 10Recurrence 4Neurofibrosarcoma 2Myeloproliferative Disorders 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Wilms Tumor 1Vascular Neoplasms 1Uterine Neoplasms 1Uterine Diseases 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Neoplasms by Site 1Neoplasms 1Myoepithelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Liposarcoma, Myxoid 1

Interventions

pembrolizumab 26Paclitaxel 25Carboplatin 19Bevacizumab 13Specimen Handling 11Magnetic Resonance Spectroscopy 9Doxorubicin 8Cisplatin 8Taxes 7Biopsy 7olaparib 6lenvatinib 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Megestrol Acetate 5Letrozole 5Gemcitabine 5Docetaxel 5trastuzumab deruxtecan 4Trastuzumab 4Tirzepatide 4Progestins 4Medroxyprogesterone Acetate 4Fluorouracil 4palbociclib 3ipatasertib 3atezolizumab 3abemaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × selinexor × 90 days × Clear all
NCT05611931 2026-05-29

XPORT-EC-042

Karyopharm Therapeutics Inc

Phase 3 Active not recruiting
257 enrolled
Gynecologic

Endometrial Neoplasms

NCT03555422 2026-04-13

ENGOT-EN5

Karyopharm Therapeutics Inc

Phase 3 Completed
263 enrolled
Gynecologic

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡